Archon Biosciences Unveils AI-Driven Antibody Cages with $20M Funding

The Seattle-based startup aims to revolutionize drug development by combining antibodies with AI-designed protein structures for targeted therapies.

Archon Biosciences, co-founded by James Lazarovits and George Ueda, has emerged from stealth mode with $20 million in seed funding for its innovative Antibody Cages (AbCs).
The startup leverages AI to design AbCs, which are new protein structures combining antibodies with computationally generated proteins to improve therapeutic targeting.
AbCs offer enhanced control over how drugs interact with specific cells, potentially overcoming challenges faced by previous antibody therapies.
The technology was developed in collaboration with the University of Washington's Baker Lab, led by Nobel laureate David Baker, and aims to address previously undruggable targets.
Archon plans to focus initial applications on cancer treatment, with preclinical testing already underway to demonstrate the platform's effectiveness.